FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

DOI: 10.1634/theoncologist.2018-0084

Keywords: Locally advanced or metastatic urothelial carcinoma, Bladder cancer, Platinum‐containing chemotherapy, Atezolizumab, Programmed death‐ligand 1 antibody, Pembrolizumab, Programmed death receptor‐1 antibody immunotherapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text